SEARCH

SEARCH BY CITATION

References

  • 1
    Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 2
    Pickering TG, Davidson K, Gerin W, et al. Masked hypertension. Hypertension. 2002;40:795796.
  • 3
    Liu JE, Roman MJ, Pini R, et al. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med. 1999;131:564572.
  • 4
    Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] study). Circulation. 2001;104:13851392.
  • 5
    Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004;291:13421349.
  • 6
    Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508515.
  • 7
    Leitao CB, Canani LH, Kramer CK, et al. Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients. Diabetes Care. 2007;30:12551260.
  • 8
    Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697716.
  • 9
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S5S10.
  • 10
    Flores L, Gimenez M, Esmatjes E. Prognostic significance of the white coat hypertension in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2006;74:2125.
  • 11
    Nielsen FS, Gaede P, Vedel P, et al. White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy. Diabetes Care. 1997;20:859863.
  • 12
    Ribeiro L, Gama G, Santos A, et al. Arterial distensibility in subjects with white-coat hypertension with and without diabetes or dyslipidaemia: comparison with normotensives and sustained hypertensives. Blood Press Monit. 2000;5:1117.
  • 13
    Shimada K, Kawamoto A, Matsubayashi K, et al. Silent cerebrovascular disease in the elderly: correlation with ambulatory pressure. Hypertension. 1990;16:692699.
  • 14
    Hougaku H, Matsumoto M, Kitagawa K, et al. Silent cerebral infarction as a form of hypertensive target organ damage in the brain. Hypertension. 1992;20:816820.
  • 15
    Kobayashi S, Okada K, Koide H, et al. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke. 1997;28:19321939.
  • 16
    Price TR, Manolio TA, Kronmal RA, et al. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke. 1997;28:11581164.
  • 17
    Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:10111053.
  • 18
    Kario K, Matsuo T, Kobayashi H, et al. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients: advanced silent cerebrovascular damage in extreme dippers. Hypertension. 1996;27:130135.
  • 19
    Kario K, Sakata T, Higashikawa M, et al. Silent cerebral infarcts in basal ganglia are advanced in congenital protein C-deficient heterozygotes with hypertension. Am J Hypertens. 2001;14:818822.
  • 20
    Eguchi K, Kario K, Shimada K. Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. Stroke. 2003;34:24712474.
  • 21
    Eguchi K, Ishikawa J, Hoshide S, et al. Impact of blood pressure vs. glycemic factors on target organ damage in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2006;8:404410.
  • 22
    Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol. 1984;4:12221230.
  • 23
    Devereux RB, Dahlof B, Levy D, et al. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol. 1996;78:6165.
  • 24
    American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):S79S83.
  • 25
    Mallion JM, Clerson P, Bobrie G, et al. Predictive factors for masked hypertension within a population of controlled hypertensives. J Hypertens. 2006;24:23652370.
  • 26
    Kobayashi S, Okada K, Koide H, et al. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke. 1997;28:19321939.
  • 27
    Kario K, Shimada K, Schwartz J, et al. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol. 2001;38:238245.
  • 28
    Bernick C, Kuller L, Dulberg C, et al. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology. 2001;57:12221229.
  • 29
    Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation. 2000;101:22712276.
  • 30
    Palmieri V, Bella JN, Arnett DK, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001;103:102107.
  • 31
    Eguchi K, Kario K, Hoshide S, et al. Type 2 diabetes is associated with left ventricular concentric remodeling in hypertensive patients. Am J Hypertens. 2005;18:2329.
  • 32
    Okin PM, Devereux RB, Gerdts E, et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation. 2006;113:15881596.
  • 33
    Equiluz-Bruck S, Schnack C, Kopp HP, et al. Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus. Am J Hypertens. 1996;9:11391143.
  • 34
    Nakano S, Ito T, Furuya K, et al. Ambulatory blood pressure level rather than dipper/nondipper status predicts vascular events in type 2 diabetic subjects. Hypertens Res. 2004;27:647656.
  • 35
    Gambardella S, Frontoni S, Spallone V, et al. Increased left ventricular mass in normotensive diabetic patients with autonomic neuropathy. Am J Hypertens. 1993;6:97102.
  • 36
    Grossman E, Shemesh J, Shamiss A, et al. Left ventricular mass in diabetes-hypertension. Arch Intern Med. 1992;152:10011004.
  • 37
    Hirayama H, Sugano M, Abe N, et al. Determination of left ventricular mass by echocardiography in normotensive diabetic patients. Jpn Circ J. 2000;64:921924.
  • 38
    Felicio JS, Ferreira SRG, Plavnik FL, et al. Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. Am J Hypertens. 2000;13:11491154.
  • 39
    Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1:14301432.
  • 40
    Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:9981004.
  • 41
    Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412419.
  • 42
    Moran A, Palmas W, Field L, et al. Cardiovascular autonomic neuropathy is associated with microalbuminuria in older patients with type 2 diabetes. Diabetes Care. 2004;27:972977.
  • 43
    Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164176.
  • 44
    Leitao CB, Canani LH, Bolson PB, et al. Urinary albumin excretion rate is associated with increased ambulatory blood pressure in normoalbuminuric type 2 diabetic patients. Diabetes Care. 2005;28:17241729.
  • 45
    Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. Prospective Diabetes Study 61. Diabetes Care. 2002;25:14101417.
  • 46
    Stergiou GS, Salgami EV, Tzamouranis DG, et al. Masked hypertension assessed by ambulatory blood pressure versus home blood pressure monitoring: is it the same phenomenon? Am J Hypertens. 2005;18:772778.